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Objectives: The prognostic utility of serum C reactive
protein (CRP) alone in sepsis is controversial. We used
decision curve analysis (DCA) to evaluate the clinical
usefulness of combining serum CRP levels with the
CUBR-65 score in patients with suspected sepsis.
Design: Retrospective cohort study.
Setting: Emergency department (ED) of an urban
teaching hospital in Japan.
Participants: Consecutive ED patients over 15 years of
age who were admitted to the hospital after having a
blood culture taken in the ED between 1 January 2010
and 31 December 2012.
Main outcome measures: 30-day in-hospital
mortality.
Results: Data from 1262 patients were analysed for
score evaluation. The 30-day in-hospital mortality was
8.4%. Multivariable analysis showed that serum CRP
≥150 mg/L was an independent predictor of death
(adjusted OR 2.0; 95% CI 1.3 to 3.1). We compared the
predictive performance of CURB-65 with the
performance of a modified CURB-65 with that included
CRP (≥150 mg/L) to quantify the clinical usefulness of
combining serum CRP with CURB-65. The areas under
the receiver operating characteristics curves of CURB-65
and a modified CURB-65 were 0.76 (95% CI 0.72 to
0.80) and 0.77 (95% CI 0.72 to 0.81), respectively. Both
models had good calibration for mortality and were
useful among threshold probabilities from 0% to 30%.
However, while incorporating CRP into CURB-65 yielded
a significant category-free net reclassification
improvement of 0.387 (95% CI 0.193 to 0.582) and
integrated discrimination improvement of 0.015 (95% CI
0.004 to 0.027), DCA showed that CURB-65 and the
modified CURB-65 score had comparable net benefits for
prediction of mortality.
Conclusions: Measurement of serum CRP added
limited clinical usefulness to CURB-65 in predicting
mortality in patients with clinically suspected sepsis,
regardless of the source.
INTRODUCTION
Sepsis is a major cause of morbidity and mor-
tality worldwide, with in-hospital mortality
still at 18% or more, according to recent
surveys in resource-rich countries.1–3 Early
identiﬁcation of high-risk patients and timely
intervention for sepsis are therefore crucial
to improving outcomes.
Severity assessment is important in the
management of patients, including decision-
making regarding choice of treatment and
patient disposition. To encourage implemen-
tation, a clinical prediction rule must be user-
friendly.4 While there are a lot of well-known
scoring systems for severity of illness such as
the Acute Physiology and Chronic Health
Evaluation (APACHE), Sepsis-related Organ
Failure Assessment (SOFA) and Multiple
Organ Dysfunction Score (MODS), they have
too many items to use conveniently in the
emergency department (ED).5 In addition,
these scores have not been well validated in
settings other than the intensive care unit
(ICU). CURB-65 is a simple prediction rule
originally developed as a prognostic scoring
system for community-acquired pneumonia
(CAP).6 The rule has been well validated in
patients with CAP, and CURB-65-guided anti-
biotic therapy has safely reduced broad-
spectrum antibiotic use in this population.7 8
In addition to its utility among patients with
Strengths and limitations of this study
▪ Combining serum C reactive protein (CRP) with
CURB-65 gave statistically significant values of
net reclassification improvement and integrated
discrimination improvement. In contrast, deci-
sion curve analysis showed that combining
serum CRP with CURB-65 was of only limited
clinical usefulness.
▪ The limitations of this study are the possibility of
selection bias of the eligible patients and the
retrospective nature of the study in a single
hospital.
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CAP, CURB-65 has also been correlated with mortality in
patients with suspected sepsis, regardless of the source,
and in patients admitted for non-surgical illness.9–11
Serum C reactive protein (CRP) is an acute phase
protein often evaluated as a marker of systemic inﬂamma-
tion.12 In Japan, serum CRP levels have been used as a
diagnostic and prognostic marker of infection in daily
clinical practice and clinical trials of new drugs.13
However, evidence demonstrating its value is insufﬁcient
at present for the routine application of serum CRP levels
to assess the severity of infection. As a prognostic marker,
some have reported that serum CRP on admission is asso-
ciated with mortality.14 15 However, a systematic review
reported conﬂicting ﬁndings, noting that serum CRP
levels were not signiﬁcantly different between a survivor
and a non-survivor, suggesting that these levels may have
limited value in reﬂecting the severity of sepsis.12 As a
diagnostic marker, the sensitivity and speciﬁcity of serum
CRP for discriminating bacterial from non-infectious
inﬂammation were only 75% and 67%, respectively,
according to a meta-analysis.16 However, while the diag-
nostic performance of serum CRP alone is limited, serum
CRP has been reported to contribute some additional
information to a prediction rule involving a patient’s
symptoms and physical examination in the diagnosis of
pneumonia.17 In this respect, the additive prognostic
value of serum CRP to an existing severity score is
unknown.
Performance of a prediction model has traditionally
been evaluated by discrimination and calibration.
However, having good discrimination and calibration
alone is not sufﬁcient to show that a model would
improve decision-making.18 As metrics of reclassiﬁcation,
net reclassiﬁcation improvement (NRI) and integrated
discrimination improvement (IDI) have enjoyed increas-
ing usage in evaluating improvement in prediction
models. However, these improvements quantiﬁed as NRI
and IDI are also not sufﬁcient for evaluating clinical use-
fulness.19–21 Decision curve analysis (DCA), which was
ﬁrst described by Vickers and Elkin, can be used to
incorporate the clinical consequences of a decision into
evaluations of diagnostic tests or prediction models.22 To
the best of our knowledge, there have been no studies
in which DCA is employed to evaluate the clinical useful-
ness of serum CRP levels and CURB-65 score in patients
with suspected sepsis.
Here, our objective was to use DCA to evaluate the
clinical usefulness of combining serum CRP levels with
the CURB-65 score in patients with suspected sepsis,
regardless of the source of infection.
MATERIALS AND METHODS
Study design, setting and patients
We performed a retrospective cohort study at Kyoto City
Hospital, an urban teaching hospital with 548 beds in
Japan. Consecutive ED patients over 15 years of age
admitted to the hospital after having a blood culture
taken in the ED between 1 January 2010 and 31
December 2012 were included. The doctor’s decision to
order a blood culture was used as a surrogate marker for
suspected sepsis as in previous studies.11 23 To facilitate
data independence, only the index admission was
included for patients with multiple admissions during
the study period. Patients transferred from another hos-
pital or who had cardiopulmonary arrest on arrival at
the hospital were excluded.
Data collection
The following data were extracted from electronic
medical records for each patient: age, gender, underlying
disease, vital signs (heart rate, blood pressure, respiratory
rate (RR), and mental confusion and body temperature),
laboratory ﬁndings (white cell count, platelet count, and
blood urea nitrogen and serum CRP levels) and
outcome. For vital signs and laboratory data, initial values
at the hospital visit were recorded. Blood pressure was
measured with a non-invasive cuff. Serum CRP was
measured with a latex turbidimetric immunoassay. The
items of the CURB-65 score were as follows: mental con-
fusion (present/absent), BUN>7 mmol/L (20 mg/dL),
RR ≥30/min, either or both systolic blood pressure
<90 mm Hg or diastolic blood pressure ≤60 mm Hg, and
age ≥65 years.6 Mental confusion was deﬁned as disorien-
tation in a person, place or time or being in a stupor or
coma as with a previous study.6
The main outcome measure was 30-day in-hospital
mortality. Patients who were discharged or transferred
from the hospital within 30 days of admission or who
remained in the hospital for more than 30 days were
considered alive in this analysis.24
Statistical analysis
First, we validated the CURB-65 model. We graphically
assessed the calibration of the CURB-65 model with a
calibration plot and tested it with the Hosmer-
Lemeshow test. A p value <0.05 indicates a lack of good
ﬁt for the model. Regarding the model discrimination,
we also computed the area under the receiver operating
characteristic curve (AUC) with a 95% CI using 500
bootstrap resampling.25 The predicted mortalities with
95% CI were calculated by introducing the CURB-65
score as a continuous variable into a univariable logistic
regression.
Second, we examined the additional value of serum
CRP. We graphically checked whether or not the rela-
tionship between the serum CRP level and mortality was
linear in the logit with a smoothing curve using a locally
weighted least squares (Lowess) regression.26 We con-
ducted logistic regression analysis after adding CRP as a
continuous variable to the CURB-65 system. User-
friendliness is important for clinical prediction rules and
dichotomised test results (normal vs abnormal) are easy
to use and interpret. We explored the cut-off point of
the serum CRP level for prediction of death in patients
with suspected sepsis because the optimal cut-off point
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was unknown. Serum CRP results were ﬁrst divided into
quartiles and rounded to the nearest 10. Each patient
was then assigned to one of four categories correspond-
ing to the CRP quartiles. We assessed the most optimal
cut-off point from the AUC. We conducted multivariable
logistic regression analysis to adjust predictors of death
by introducing prespeciﬁed variables: items of CURB-65.
We assessed multicollinearity using the variance inﬂation
factor (VIF). VIFs greater than 2.5 may be problematic.27
We also computed the unadjusted OR of covariates
using univariable logistic regression to show the inﬂu-
ence of adjustment for predictors.
Third, we assessed the model performance of the
modiﬁed CURB-65 score, which was made by incorporat-
ing CRP information into the CURB-65 model, using a
calibration plot and Hosmer-Lemeshow test for calibra-
tion and AUC for discrimination. Additive information
of CRP was evaluated by category-free NRI and IDI.28
With regard to clinical usefulness, we examined the net
beneﬁt using DCA.22 Brieﬂy, the method is based on the
principle that the relative harms of false positives and
false negatives can be expressed in terms of a probability
threshold.29 The net beneﬁt is obtained by subtracting
the proportion of patients who are false positive from
the proportion who are true positive, weighting by the
relative harm of a false-positive and a false-negative
result. The net beneﬁt of making a decision based on
the model can be calculated with the following formula:







where n is the total number of patients in the study and
Pt is a given threshold probability.
22 29 30
With regard to sample size estimation, at least 8–10
events per variable are required for reliable multiple
logistic regression analysis,31 32 and 100 events and 100
non-events are required for an external validation
study.33 We assumed 30–40 deaths per year among eli-
gible patients, collecting 3 years’ worth of data (90–120
estimated deaths) to appropriately conduct multiple
logistic regressions with 11 variables and ensure
adequate statistical power.
In terms of handling missing values, we planned to
perform a complete case analysis if missing values were
below 5%, as such an analysis might then be feasible.34
If missing values were above 5%, we planned to apply an
appropriate imputation method.
Data were analysed with R software V.3.0.1 (http://
www.r-project.org) and Stata software, V.13 (StataCorp.,
College Station, Texas, USA) including programmes of
Decision Curve Analysis provided by Vickers.35
RESULTS
Patient characteristics
Among 1310 eligible patients over 3 years of study, 108
deaths (8.2% mortality) were recorded. Demographics,
underlying diseases, vital signs, laboratory ﬁndings and
chief diagnosis for admission were presented in table 1.
Diagnosis was unclear in 92 patients (7.3%). RRs data
were missing for 21 patients, and CRP data were
missing for 28 patients (table 3). Overall cases with any
missing predictor were 48 in number (3.7%), so we
conducted a complete case analysis, leaving 1262
patients (106 deaths, 8.4% mortality) for model evalu-
ation analyses.




Age (years), median (IQR) 76 (64–83)
Female, n (%) 560 (44.4)
Nursing home resident, n (%) 37 (2.9)
Underlying diseases, n (%)
Cerebrovascular disease 156 (12.4)
Congestive heart failure 101 (8.0)
Chronic respiratory disease 155 (12.3)
Chronic kidney disease 100 (7.9)
Chronic liver disease 77 (6.1)
Diabetes mellitus 243 (19.3)
Malignancy 222 (17.6)
Dementia 121 (9.6)
Autoimmune disorder 63 (5.0)
HIV positive 3 (0.2)
Vital signs
Heart rate (beats/min), median (IQR) 98 (85–156)









Mental confusion, n (%) 215 (17.0)
Laboratory data
White blood cell count (109/L),
median (IQR)
10.5 (7.6–14.6)
Platelet count (×109/L), median (IQR) 196 (150–256)
C reactive protein (mg/L),
median (IQR)
72.3 (18.2–149.2)
Blood urea nitrogen (mmol/L),
median (IQR)
6.9 (5.0–10.2)
Chief diagnosis for admission
Pneumonia 393 (33.6)
Urinary tract infection 188 (16.1)
Skin and Soft tissue infection 62 (5.3)
Acute cholangitis 47 (4.0)
Acute cholecystitis 33 (2.8)
Bowel perforation 21 (1.8)
Other bacterial infection 150 (12.8)
Non-bacterial infection 103 (8.8)
Non-infection 174 (14.9)
Unclear 92 (7.3)
Bacteraemia, n (%) 210 (16.6)
30-day in-hospital mortality, n (%) 106 (8.4)
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Validation of CURB-65 in our population
Observed 30-day in-hospital mortalities and predicted
mortalities computed by the CURB-65 score are shown
in table 4. CURB-65 showed good calibration for mortal-
ity, with a Hosmer-Lemeshow test of 4.08 (df=5,
p=0.538), indicating good ﬁt. The calibration plot is
shown in online supplementary ﬁgure S1A. The AUC
for CURB-65 was 0.76 (95% CI 0.72 to 0.80; online sup-
plementary ﬁgure S2).
Evaluation of CRP as a predictor of mortality
The relationship between the serum CRP level and mor-
tality was almost linear in the logit (see online supple-
mentary ﬁgure S3). An unadjusted OR for mortality was
1.05 (95% CI 1.03 to 1.07) per 10 mg/L rise in the serum
CRP level. The addition of a continuous serum CRP level
to the CURB-65 system revealed that an adjusted OR for
mortality was 1.04 (95% CI 1.01 to 1.06) per 10 mg/L
increase in concentration. Since the optimal cut-off point
was unknown, the serum CRP results were divided into
quartiles: the quartile points were 18.2, 72.3 and
149.2 mg/L. Then they were rounded to the nearest 10,
and we set interim cut-off points as 20, 70 and 150 mg/L.
Observed mortality and unadjusted ORs for mortality of
each CRP group are shown in table 2. We repeated
regression analyses adding serum CRP as a dichotomised
variable with each interim cut-off point. We found
150 mg/L to be the most optimal threshold to dichotom-
ise serum CRP levels.
Adjusted ORs for mortality are shown in table 3. We
found no evidence of multicollinearity because the VIFs
for predictors in the model in table 3 were less than 1.2.
We identiﬁed a serum CRP level ≥150 mg/L as an inde-
pendent predictor of death in patients with clinically sus-
pected sepsis.
Additive information of CRP to CURB-65
Since the adjusted OR (ie, regression coefﬁcient) of CRP
was comparable to each item in CURB-65, we made a
modiﬁed CURB-65 score by adding one point to the
CURB-65 score when the serum CRP level was
≥150 mg/L. Table 4 shows observed the 30-day in-hos-
pital mortalities and predicted mortalities stratiﬁed by
the modiﬁed CURB-65 score. The modiﬁed CURB-65
also showed good calibration for mortality, with a
Hosmer-Lemeshow test of 4.52 (df=6, p=0.607). The cali-
bration plot is shown in online supplementary ﬁgure
S1B. The AUC for the modiﬁed CURB-65 was 0.77 (95%
CI 0.72 to 0.81; online supplementary ﬁgure S2). By
incorporating CRP into CURB-65, event NRI was −0.151
and non-event NRI was 0.538, giving an overall category-
free NRI of 0.387 (95% CI 0.193 to 0.582, p<0.0001).
Further, IDI for events was 0.014 and IDI for non-events
was 0.001, giving an overall IDI of 0.015 (95% CI 0.004
to 0.027, p<0.01). These ﬁndings were statistically
signiﬁcant.
Decision curve analysis
Figure 1 demonstrates the decision curves for CURB-65
and modiﬁed CURB-65 to predict 30-day in-hospital mor-
tality in patients with clinically suspected sepsis. Both
CURB-65 and the modiﬁed CURB-65 are useful between
threshold probabilities of 0–30%. However, both curves
cross and depict little difference in net beneﬁt. The net
Table 3 Adjusted ORs for mortality in multivariable logistic regression analyses
Variables Unadjusted ORs (95% CI) Adjusted ORs* (95% CI) Missing n, (%)
CRP≥150 mg/L 2.5 (1.6 to 3.7) 2.0 (1.3 to 3.1) 28 (2.1)
Age≥65 years 3.7 (1.9 to 7.3) 2.3 (1.1 to 4.6) 0 (0)
Mental confusion 2.9 (1.9 to 4.5) 2.1 (1.3 to 3.4) 0 (0)
Hypotension (SBP<90 or DBP≤60 mm Hg) 3.0 (2.0 to 4.5) 2.1 (1.3 to 3.2) 0 (0)
Tachypnoea (RR≥30/min) 3.1 (2.0 to 4.8) 2.4 (1.5 to 3.9) 21 (1.6)
BUN>7 mmol/L 4.7 (2.9 to 7.6) 2.7 (1.6 to 4.5) 0 (0)
Overall – – 48 (3.7)
*Adjusted for items of CURB-65.
BUN, blood urea nitrogen; CRP, C reactive protein; DBP, diastolic blood pressure; RR, respiratory rate; SBP, systolic blood pressure.







0.1–19.9 4.0 (13/326) 1 (reference)
20–69.9 6.6 (19/289) 1.7 (0.8 to 3.5)
70–149.9 8.7 (29/335) 2.3 (1.2 to 4.5)
≥150 14.4 (45/312) 4.1 (2.1 to 7.7)
*Calculated by univariable logistic regression.
CRP, C reactive protein.
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beneﬁts at each point of the CURB-65 score and the
modiﬁed CURB-65 score are shown in table 4. The com-
parison of discrimination, calibration, reclassiﬁcation
metrics and clinical usefulness between CURB-65 and
modiﬁed CURB-65 are summarised in table 5.
To assess the robustness of our ﬁndings, we repeated
DCA with changing the cut-off level of serum CRP as 20
and 70 mg/L, respectively, in sensitivity analyses.
Similarly, we found that the additive clinical usefulness
of serum CRP was unremarkable.
DISCUSSION
We determined that having high CRP levels was inde-
pendently associated with high mortality in our
population. We also conﬁrmed geographical and
domain validation of CURB-65 in our patients, which
comprised an external validation in a different geo-
graphical area and in a population including a different
category of patients from CAP.4
The utility of serum CRP as a prognostic marker has
been found to vary.12 In Japan, universal health coverage
allows people to consult a doctor soon after they recog-
nise any symptoms, with no particular limitations.36
Given that the secretion of CRP peaks at 36–50 h after
inﬂammatory stimulus,12 the serum CRP level might be
useful as a surrogate marker of duration from disease
onset to consulting a doctor as well as a marker reﬂect-
ing the intensity of inﬂammation. We believe that the
association between the serum CRP level and mortality
will be more easily identiﬁed in countries such as Japan
where the population has easy access to hospitals, due to
the wide distribution in duration from disease onset to
visiting a hospital. Although reclassiﬁcation metrics such
as NRI and IDI were statistically improved on incorpor-
ation of the CRP level, the additive clinical usefulness of
CRP to CURB-65 was admittedly limited (table 5).
Strengths and limitations of the study
A major strength of this study is our evaluation using
DCA. To the best of our knowledge, this is the ﬁrst study
which examined the clinical usefulness of serum CRP
and the CURB-65 score in septic patients using DCA.
DCA can take into account risk threshold, weighting
beneﬁts and harms, and is useful in evaluating the clin-
ical utility of a prediction model.21 22 37 For instance,
the net beneﬁt of 0.061 at a threshold probability of 3%
in the CURB-65 score can be interpreted as meaning
that making a decision based on the prediction model,
compared to assuming that all patients would be alive,
leads to the equivalent of a net 6.1 true-positive results
per 100 patients with no corresponding increase in the
number of false-positive results (table 4).22 In our popu-
lation, an 8.4% overall 30-day in-hospital mortality
means a maximum net beneﬁt of 0.084, which is
























0 0 (0/190) 1 (0.7 to 2.1) 0.075 0 0 (0/152) 1 (0.6 to 2.0) 0.075
1 3 (9/334) 3 (2.0 to 4.2) 0.061 1 2 (7/287) 2 (1.6 to 3.6) 0.068
2 8 (33/409) 7 (5.2 to 8.3) 0.034 2 6 (23/381) 5 (4.0 to 6.9) 0.048
3 13 (34/254) 14 (11.9 to 17.2) 0.015 3 12 (32/265) 11 (9.2 to 13.3) 0.024
4 30 (25/84) 28 (22.5 to 35.2) 0.004 4 17 (22/129) 22 (17.7 to 26.5) 0.012
5 39 (7/18) 48 (37.0 to 60.1) 0 5 44 (18/41) 38 (29.9 to 47.8) 0.005
6 57 (4/7) 58 (45.2 to 70.4) 0
*The modified CURB-65 score was made by the addition of 1 point if CRP≥150 mg/L.
†Predicted mortality was calculated by introducing CURB-65 and the modified CURB-65 score as a continuous variable into univariable
logistic regression.
‡Net benefits were calculated for each predicted mortality as a threshold probability.
CRP, C reactive protein.
Figure 1 Decision curves for the CURB-65 and modified
CURB-65 (mCURB-65) to predict 30-day mortality in patients
with suspected sepsis. The thick black line is the net benefit
of treating no patients, assuming that all would be alive; the
thin grey line is the net benefit of treating all patients similarly
regardless of their severity, assuming that all would die; the
long dashed line is the net benefit of treating patients
according to the CURB-65 score; and the thin black line is
the net benefit of treating patients based on the modified
CURB-65 score.
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calculated if we use a threshold probability of 0%. There
are no universally accepted criteria on the patient’s risk
threshold for suspected sepsis to make a decision about
patient disposition or therapeutic indication. If we
extrapolate the data on CAP, low, intermediate and high
risk of mortality are considered to be about 1–2%, 8–9%
and 20–30%, respectively.6 The ability to make better
decisions with serum CRP than without was considered
to be unremarkable in this range of risk threshold.
Our study is a type of external validation study with
model updating to assess whether the serum CRP level
has additive value to CURB-65 or not.4 Another strength
of this study might be our sample size with adequate stat-
istical power for an external validation study.33
Several limitations to the present study warrant
mention. We cannot rule out the possibility of selection
bias, as only inpatients who had a blood culture taken
were included. We may therefore have missed patients
with infection who did not undergo blood culture in the
ED; again, contrarily, some patients without infection
were included in the study. However, clinicians must rou-
tinely make decisions in the ED despite being unsure as
to whether or not a patient is actually infected; we there-
fore considered it important to evaluate a clinical predic-
tion rule accounting for such clinical uncertainty.
Inclusion of patients without infectious diseases, we feel,
reﬂects a real-world scenario. Another limitation is the
retrospective nature of the study and the fact that it was
conducted in a single hospital. Given the study’s retro-
spective design, patients with a high CRP might have
received more intensive therapy than those with a rela-
tively low CRP. Such bias might have lowered the predict-
ive ability of CRP.
CONCLUSIONS
While the serum CRP level ≥150 mg/L was found to be
associated with high mortality, its additive clinical useful-
ness to CURB-65 was limited based on DCA. CURB-65
correlated well with 30-day in-hospital mortality in
patients with clinically suspected infection, and it was
useful among threshold probabilities in the range of
0–30%. Measurement of serum CRP may contribute
little to making decisions regarding the management of
patients with clinically suspected sepsis.
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